Valvular and Structural Heart Diseases
TAVR and SAVR in ESRD: Just because we can doesn't necessarily mean that we should
Key Points
- In patients with end stage renal disease on hemodialysis, TAVR resulted in reduced length of stay, hospitalization cost, complication rate and higher rates of home discharge compared to SAVR.
- In-hospital mortality and complication rates were high in both groups.
- Careful patient selection and further research is required to identify patients with end-stage renal disease who might, or might not, benefit from intervention.
CONFLICT OF INTEREST
Dr Webb is a consultant to and receives research support from Edwards Lifesciences, Abbott Vascular and Boston Scientific.
